Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13328898 | 0.93 | TSHR (0.45) | TSHRGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13249786 | 0.93 | TSHR (0.45) | TSHRGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13250063 | 0.88 | PARP1 (0.40) | TSHRALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL13249798 | 0.87 | PPARG (0.41) | TSHRGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13328901 | 0.87 | PPARG (0.41) | TSHRGAASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13249799 | 0.86 | TP53 (0.40) | TSHRGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL13328904 | 0.86 | MTHFD2 (0.39) | TSHRGAASMN1; SMN2L3MBTL1LMNA | |
| SCHEMBL13249802 | 0.85 | KDR (0.45) | GAAALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL13249789 | 0.85 | PPARG (0.42) | TSHRGAAALDH1A1LMNATP53 | |
| SCHEMBL13328906 | 0.85 | PPARG (0.42) | TSHRGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190687-A1 | PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR65 | TSHR 1056/4885GAA 1215/4885SMN1; SMN2 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.